Fundz

Eikon Therapeutics

Millbrae, California, United States · Biotechnology, Health Care, Therapeutics

Eikon Therapeutics is advancing breakthrough therapies through the purposeful integration of science and engineering. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to pe

You have opened 5 full company profiles today. Create an account to keep reading them. Create an account

Key facts

Headquarters
Millbrae, California, United States
Employees
390
Industries
Biotechnology, Health Care, Therapeutics
Status
Public (EIKN)
Website
eikontx.com
LinkedIn
Company page

Recent activity at Eikon Therapeutics

  • : SEC 8-K (8.01): On October 26, 2026, the Company presented updated clinical trial data for EIK1001 at the ESMO Congress, detailing the open-label TeLuRide-005 trial which involved 72 participants with advanced stage 4 non-small cell lung cancer (NSCLC). The data indicates that EIK1001, used in combination with pembrolizumab and chemotherapy, shows a potentially durable effect and a favorable tolerability profile for outpatient administration. At the efficacy data cutoff on October 1, 2026, the combination therapy yielded a 63.1% objective response rate (ORR) and a 89.2% disease control rate (DCR). The trial is significant as it could position EIK1001 as a key differentiator in the treatment of NSCLC compared to previous therapies, especially considering the manageable adverse events associated with the drug regimen. This strategic update holds potential implications for future treatment protocols and market positioning.
  • : SEC 8-K (8.01): On October 23, 2026, the Company presented significant clinical data regarding EIK1003, a selective non-brain-penetrant PARP1 inhibitor, during the 2026 European Society for Medical Oncology Congress. Updated results for EIK1003, which has been administered to 65 participants suffering from various cancers, indicate that it was well-tolerated across multiple dose levels and demonstrated promising antitumor activity in combination with the hormonal agent abiraterone and weekly paclitaxel. The objective response rate (ORR) was reported at 14.3% overall in efficacy-evaluable participants, with higher responses noted in PARP-naïve patients. This presentation marks a continuation of data expansion from previously reported findings and could have substantial implications for the treatment landscape of tumors with specific genetic backgrounds.
  • : Eikon Therapeutics Appoints Ching-Pin Chang as Chief Scientific Officer

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Employee benefit plans

Eikon Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

About Eikon Therapeutics: questions and answers

What does Eikon Therapeutics do?

Eikon Therapeutics is advancing breakthrough therapies through the purposeful integration of science and engineering. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to pe

Where is Eikon Therapeutics headquartered?

Eikon Therapeutics is headquartered in Millbrae, California, United States.

How many employees does Eikon Therapeutics have?

Eikon Therapeutics has about 390 employees.

What is the latest news on Eikon Therapeutics?

On Oct 23, 2026, SEC 8-K (8.01): On October 26, 2026, the Company presented updated clinical trial data for EIK1001 at the ESMO Congress, detailing the open-label TeLuRide-005 trial which involved 72 participants with advanced stage 4 non-small cell lung cancer (NSCLC). The data indicates that EIK1001, used in combi

Is Eikon Therapeutics a public company?

Yes. Eikon Therapeutics is publicly traded under the ticker EIKN.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Eikon Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.